Market Cap 4.31M
Revenue (ttm) 1.73M
Net Income (ttm) -23.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,350.29%
Debt to Equity Ratio -0.31
Volume 540,400
Avg Vol 573,978
Day's Range N/A - N/A
Shares Out 8.63M
Stochastic %K 2%
Beta 1.16
Analysts Strong Sell
Price Target $14.94

Company Profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response a...

Industry: Medical Devices
Sector: Healthcare
Phone: 512 774 8930
Address:
1489 West Warm Springs Road, Suite 110, Henderson, United States
BinaryLogic
BinaryLogic Aug. 19 at 9:54 AM
$VNRX [Again] Strained liquidity position, new/additional equity placement most likely, imminent with SP target $0.15-0.30 as noted here (below). Sep-Dec transformative catalysts possible (IMO) with licensing deal(s) including Sysmex, $5.0M publication-based payment and reimbursement decision. Wait for the opportunity (IMO), should it present itself ahead of the catalysts listed. Material liquidity risk currently that needs to be resolved - otherwise, warrant conversions/ATM will continue to provide relentless downward pressure (IMO).
0 · Reply
Ramseydog
Ramseydog Aug. 19 at 1:41 AM
🚀 $NICH is quietly building something bigger than another supplement brand — NutraVeri is becoming the infrastructure layer for the entire category. In ~60 seconds founders get a free, deterministic NutraVeri Score across 6 dimensions (formula strength, ingredient evidence, claim risk, dose, label readiness, market fit) built on actual FDA/FTC warning letters and public data. No black-box AI, no account required. Recent moves: expanding into full commercialization (warehousing, fulfillment, distribution), active JV talks with a major U.S. cGMP facility, and now opening the Label Readiness Engine to retired NFL players who want to own their own products instead of just endorsing someone else’s. From concept → scored → manufactured → customer doorstep. That’s the play in a tightening regulatory environment. Watch this one. 💪 $CRDL $AIMN $VNRX $DNA #NICH #NutraVeri #Supplements #Wellness #cGMP #Biotech https://grok.com/share/bGVnYWN5_c2efe96f-46dc-4d5e-8fa7-a3e5d32a1679
0 · Reply
jetty323
jetty323 Aug. 18 at 7:36 PM
$VNRX Lagoda needs to become the activist thats needed to have Raynolds removed as CEO and bring a real business person in. The current BOD obviously is not concerned about the length of time this process has taken and the lack of sales that has occurred. The current leadership needs a solid kick in the ass to get this moving
0 · Reply
ShangVXO
ShangVXO Aug. 18 at 10:31 AM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $VNRX & $HODO on my mind
0 · Reply
SerendipiTea
SerendipiTea Aug. 17 at 10:43 PM
$VNRX Management could make some significant buys at these levels to inject some enthusiasm and confidence back into the stock. Down to a $7M cap, for a technology that has a market potential of $30B. Unbelievable how cheap it is, but also a pretty accurate reflection of no confidence in senior leadership.
1 · Reply
Samuelstark
Samuelstark Aug. 17 at 10:08 PM
$VNRX so many potential catalysts in Q3
1 · Reply
_Jessikah_J_Liu_
_Jessikah_J_Liu_ Aug. 16 at 11:06 PM
Finalizing watchlist for next week. $ACXP & $VNRX both look bottomed following earnings. If they confirm I will look to scale some. I won't retire on these trades but a move back over VWAP would be fairly low-risk, respectable gains. My crush this week is obv $IPST . Continuation signals off a strong Friday push. Low float, low risk, low borrow. Known for triple-digit moves. Like $AIFA I think this one will give multiple trade opportunities. Good luck everyone!
1 · Reply
hrtom43
hrtom43 Aug. 14 at 3:57 PM
$VNRX earning is that bad this thing is dumping
1 · Reply
VinWeezel
VinWeezel Aug. 14 at 1:08 PM
$VNRX Mayo Clinic mentioned at the end there. Need maxim to want this running. Cash time Michael?
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 14 at 10:35 AM
VNRX Q2 2026 Earnings Summary $VNRX https://stocktwits.com/news/earnings/ai summaries/vnrx-q2-2026-earnings-summary/cZotWpDRJiH
0 · Reply
Latest News on VNRX
VolitionRx reports Q2 revenue $400K, consensus $474.34K

2026-08-16T14:09:56.000Z - 2 days ago

VolitionRx reports Q2 revenue $400K, consensus $474.34K


VolitionRx Earnings Call Transcript: Q2 2026

Aug 14, 2026, 8:30 AM EDT - 5 days ago

VolitionRx Earnings Call Transcript: Q2 2026


VolitionRx Earnings release: Q2 2026

Aug 14, 2026, 8:30 AM EDT - 5 days ago

VolitionRx Earnings release: Q2 2026


VolitionRx Quarterly report: Q2 2026

Aug 14, 2026, 8:30 AM EDT - 5 days ago

VolitionRx Quarterly report: Q2 2026


VolitionRx Slides: Corporate presentation

Aug 1, 2026, 8:00 AM EDT - 18 days ago

VolitionRx Slides: Corporate presentation


VolitionRx Slides: Corporate presentation

Jul 21, 2026, 7:00 AM EDT - 4 weeks ago

VolitionRx Slides: Corporate presentation


VolitionRx Registration statement: Registration filing

Jul 10, 2026, 8:00 AM EDT - 5 weeks ago

VolitionRx Registration statement: Registration filing


VolitionRx resumed with a Buy at Maxim

2026-06-18T12:46:44.000Z - 2 months ago

VolitionRx resumed with a Buy at Maxim


VolitionRx announces collaboration with Sysmex

2026-06-17T12:21:03.000Z - 2 months ago

VolitionRx announces collaboration with Sysmex


VolitionRx Announces Collaboration with Sysmex

Jun 17, 2026, 8:15 AM EDT - 2 months ago

VolitionRx Announces Collaboration with Sysmex


VolitionRx Announces Pricing of $4.6 Million Public Offering

Jun 7, 2026, 6:30 PM EDT - 2 months ago

VolitionRx Announces Pricing of $4.6 Million Public Offering


VolitionRx Proxy statement: Proxy filing

Jun 2, 2026, 8:00 AM EDT - 2 months ago

VolitionRx Proxy statement: Proxy filing


VolitionRx Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

VolitionRx Earnings Call Transcript: Q1 2026


VolitionRx Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

VolitionRx Earnings release: Q1 2026


VolitionRx Quarterly report: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

VolitionRx Quarterly report: Q1 2026


VolitionRx Slides: Corporate presentation

May 15, 2026, 7:00 AM EDT - 3 months ago

VolitionRx Slides: Corporate presentation


VolitionRx reports Q1 revenue $1M, consensus $409,920

2026-05-14T21:21:26.000Z - 3 months ago

VolitionRx reports Q1 revenue $1M, consensus $409,920


VolitionRx Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 3 months ago

VolitionRx Proxy statement: Proxy filing


VolitionRx submits manuscript for Nu.Q Vet cancer test in cats

2026-05-07T06:07:48.000Z - 3 months ago

VolitionRx submits manuscript for Nu.Q Vet cancer test in cats


VolitionRx announces milestone in nucleosomes detection

2026-04-29T14:40:22.000Z - 3 months ago

VolitionRx announces milestone in nucleosomes detection


VolitionRx’s compliance plan accepted by NYSE American

2026-04-23T12:21:08.000Z - 4 months ago

VolitionRx’s compliance plan accepted by NYSE American


VolitionRx downgraded to Hold from Buy at D. Boral Capital

2026-04-20T12:05:06.000Z - 4 months ago

VolitionRx downgraded to Hold from Buy at D. Boral Capital


Volition Launches rNuQ™ Webshop Broadening Product Range

Apr 20, 2026, 7:30 AM EDT - 4 months ago

Volition Launches rNuQ™ Webshop Broadening Product Range


VolitionRx Earnings Call Transcript: Q4 2025

Apr 1, 2026, 8:30 AM EDT - 5 months ago

VolitionRx Earnings Call Transcript: Q4 2025


VolitionRx Annual report: Q4 2025

Apr 1, 2026, 8:30 AM EDT - 5 months ago

VolitionRx Annual report: Q4 2025


VolitionRx Earnings release: Q4 2025

Apr 1, 2026, 8:30 AM EDT - 5 months ago

VolitionRx Earnings release: Q4 2025


VolitionRx Slides: Corporate presentation

Apr 1, 2026, 7:00 AM EDT - 5 months ago

VolitionRx Slides: Corporate presentation


Why is VolitionRX Stock (VNRX) Up 24% Today?

2026-03-25T13:04:07.000Z - 5 months ago

Why is VolitionRX Stock (VNRX) Up 24% Today?


Volition Announces Detection of Over 95% of Early-Stage Cancers

Mar 25, 2026, 8:17 AM EDT - 5 months ago

Volition Announces Detection of Over 95% of Early-Stage Cancers


VolitionRx Proxy statement: Proxy Filing

Feb 11, 2026, 7:00 AM EST - 6 months ago

VolitionRx Proxy statement: Proxy Filing


VolitionRx receives non-compliance notice from NYSE American

2026-02-09T22:25:09.000Z - 6 months ago

VolitionRx receives non-compliance notice from NYSE American


VolitionRx Registration statement: Registration Filing

Feb 9, 2026, 7:00 AM EST - 6 months ago

VolitionRx Registration statement: Registration Filing


VolitionRx Proxy statement: Proxy Filing

Jan 26, 2026, 7:00 AM EST - 7 months ago

VolitionRx Proxy statement: Proxy Filing


Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

Jan 20, 2026, 8:25 AM EST - 7 months ago

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test


Volition Sponsors Symposium at Veterinary Meeting and Expo

Jan 16, 2026, 8:45 AM EST - 7 months ago

Volition Sponsors Symposium at Veterinary Meeting and Expo


VolitionRx Secures $2.0 Million in Funding

Jan 8, 2026, 9:15 AM EST - 7 months ago

VolitionRx Secures $2.0 Million in Funding


VolitionRx Slides: Corporate Presentation

Jan 8, 2026, 7:00 AM EST - 7 months ago

VolitionRx Slides: Corporate Presentation


Volition Issues Business Review 2025

Dec 17, 2025, 8:45 AM EST - 8 months ago

Volition Issues Business Review 2025


VolitionRx Earnings Call Transcript: Q3 2025

Nov 14, 2025, 8:30 AM EST - 9 months ago

VolitionRx Earnings Call Transcript: Q3 2025


VolitionRx Quarterly report: Q3 2025

Nov 14, 2025, 8:30 AM EST - 9 months ago

VolitionRx Quarterly report: Q3 2025


VolitionRx Earnings release: Q3 2025

Nov 14, 2025, 8:30 AM EST - 9 months ago

VolitionRx Earnings release: Q3 2025


VolitionRx Transcript: Status Update

Oct 8, 2025, 11:00 AM EDT - 11 months ago

VolitionRx Transcript: Status Update


Volition Sponsors Upcoming GenomeWeb Webinar

Oct 2, 2025, 8:45 AM EDT - 11 months ago

Volition Sponsors Upcoming GenomeWeb Webinar


Volition Signs Co-Marketing and Services Agreement with Hologic

Sep 29, 2025, 9:30 AM EDT - 11 months ago

Volition Signs Co-Marketing and Services Agreement with Hologic

HOLX


VolitionRx Slides: Corporate Presentation

Sep 11, 2025, 7:00 AM EDT - 1 year ago

VolitionRx Slides: Corporate Presentation


Volition Signs First Human Out Licensing Deal

Sep 9, 2025, 8:45 AM EDT - 1 year ago

Volition Signs First Human Out Licensing Deal


VolitionRx Slides: Corporate Presentation

Aug 29, 2025, 7:00 AM EDT - 1 year ago

VolitionRx Slides: Corporate Presentation


VolitionRx Earnings Call Transcript: Q2 2025

Aug 15, 2025, 8:30 AM EDT - 1 year ago

VolitionRx Earnings Call Transcript: Q2 2025


VolitionRx Quarterly report: Q2 2025

Aug 15, 2025, 8:30 AM EDT - 1 year ago

VolitionRx Quarterly report: Q2 2025


VolitionRx Earnings release: Q2 2025

Aug 15, 2025, 8:30 AM EDT - 1 year ago

VolitionRx Earnings release: Q2 2025


VolitionRx Slides: Corporate Presentation

Aug 14, 2025, 4:00 PM EDT - 1 year ago

VolitionRx Slides: Corporate Presentation


BinaryLogic
BinaryLogic Aug. 19 at 9:54 AM
$VNRX [Again] Strained liquidity position, new/additional equity placement most likely, imminent with SP target $0.15-0.30 as noted here (below). Sep-Dec transformative catalysts possible (IMO) with licensing deal(s) including Sysmex, $5.0M publication-based payment and reimbursement decision. Wait for the opportunity (IMO), should it present itself ahead of the catalysts listed. Material liquidity risk currently that needs to be resolved - otherwise, warrant conversions/ATM will continue to provide relentless downward pressure (IMO).
0 · Reply
Ramseydog
Ramseydog Aug. 19 at 1:41 AM
🚀 $NICH is quietly building something bigger than another supplement brand — NutraVeri is becoming the infrastructure layer for the entire category. In ~60 seconds founders get a free, deterministic NutraVeri Score across 6 dimensions (formula strength, ingredient evidence, claim risk, dose, label readiness, market fit) built on actual FDA/FTC warning letters and public data. No black-box AI, no account required. Recent moves: expanding into full commercialization (warehousing, fulfillment, distribution), active JV talks with a major U.S. cGMP facility, and now opening the Label Readiness Engine to retired NFL players who want to own their own products instead of just endorsing someone else’s. From concept → scored → manufactured → customer doorstep. That’s the play in a tightening regulatory environment. Watch this one. 💪 $CRDL $AIMN $VNRX $DNA #NICH #NutraVeri #Supplements #Wellness #cGMP #Biotech https://grok.com/share/bGVnYWN5_c2efe96f-46dc-4d5e-8fa7-a3e5d32a1679
0 · Reply
jetty323
jetty323 Aug. 18 at 7:36 PM
$VNRX Lagoda needs to become the activist thats needed to have Raynolds removed as CEO and bring a real business person in. The current BOD obviously is not concerned about the length of time this process has taken and the lack of sales that has occurred. The current leadership needs a solid kick in the ass to get this moving
0 · Reply
ShangVXO
ShangVXO Aug. 18 at 10:31 AM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $VNRX & $HODO on my mind
0 · Reply
SerendipiTea
SerendipiTea Aug. 17 at 10:43 PM
$VNRX Management could make some significant buys at these levels to inject some enthusiasm and confidence back into the stock. Down to a $7M cap, for a technology that has a market potential of $30B. Unbelievable how cheap it is, but also a pretty accurate reflection of no confidence in senior leadership.
1 · Reply
Samuelstark
Samuelstark Aug. 17 at 10:08 PM
$VNRX so many potential catalysts in Q3
1 · Reply
_Jessikah_J_Liu_
_Jessikah_J_Liu_ Aug. 16 at 11:06 PM
Finalizing watchlist for next week. $ACXP & $VNRX both look bottomed following earnings. If they confirm I will look to scale some. I won't retire on these trades but a move back over VWAP would be fairly low-risk, respectable gains. My crush this week is obv $IPST . Continuation signals off a strong Friday push. Low float, low risk, low borrow. Known for triple-digit moves. Like $AIFA I think this one will give multiple trade opportunities. Good luck everyone!
1 · Reply
hrtom43
hrtom43 Aug. 14 at 3:57 PM
$VNRX earning is that bad this thing is dumping
1 · Reply
VinWeezel
VinWeezel Aug. 14 at 1:08 PM
$VNRX Mayo Clinic mentioned at the end there. Need maxim to want this running. Cash time Michael?
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 14 at 10:35 AM
VNRX Q2 2026 Earnings Summary $VNRX https://stocktwits.com/news/earnings/ai summaries/vnrx-q2-2026-earnings-summary/cZotWpDRJiH
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 14 at 10:30 AM
$VNRX Q2 '26 Earnings Results & Recap VolitionRx Limited reported total revenues of $0.4 million for the three months ended June 30, 2026, and $1.4 million for the six months ended June 30, 2026, reflecting ongoing commercialization activities.
0 · Reply
BinaryLogic
BinaryLogic Aug. 14 at 2:21 AM
$VNRX [Again] The Company has an ATM and warrant conversion that will likely continue to drive the SP lower near term. Revenue and margins are not as important (IMO) as the licensing deals under consideration. The probability of at/least one licensing deal over the next 6mos is 50-75% (IMO). Up front cash, milestone payments and royalties on a $7M market cap will improve the liquidity position organically, further validate the underlying IP, provide a cash runway to CaptureSeq (cancer) licenses and others. It also will relieve compliance pressure. Sysmex is the most likely (lead) candidate for a licensing partnership. Multiplier upside intermediate term, but the fallout should continue near term. Grossly Oversold (RSI sub-terranean) on both the 1YR Daily and 3YR Weekly. https://www.stocktitan.net/news/VNRX/volition-rx-limited-announces-second-quarter-2026-financial-results-0fbq5uc69upf.html
0 · Reply
Samuelstark
Samuelstark Aug. 13 at 9:39 PM
$VNRX https://finance.yahoo.com/healthcare/articles/volitionrx-limited-announces-second-quarter-201000456.html
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 12 at 6:07 PM
BioMedNewsBreaks — $VNRX Reports Strong Correlation for Finger-Prick Nu.Q NETs Prototype in Sepsis Patients https://ibn.fm/81Vlm
0 · Reply
Samuelstark
Samuelstark Aug. 12 at 5:41 PM
$VNRX https://finance.yahoo.com/healthcare/articles/volition-demonstrates-utility-rapid-point-121700401.html
0 · Reply
Undervalued1123
Undervalued1123 Aug. 12 at 3:33 PM
$VNRX is this going to hit $2.25 by December?
4 · Reply
joshszary
joshszary Aug. 12 at 1:12 PM
$VNRX Reentered yesterday at $.69 after getting stopped out a shile back when it was $1.10. Hoping for great news on Friday and momentum leading up to the call.
0 · Reply
PhillyCA1
PhillyCA1 Aug. 12 at 1:08 PM
0 · Reply
Pukkaa56
Pukkaa56 Aug. 12 at 5:40 AM
0 · Reply
Modo6177
Modo6177 Aug. 10 at 3:18 AM
$VNRX those calls are actually making some money… interesting. Lotto play.
0 · Reply
VinWeezel
VinWeezel Aug. 9 at 6:56 PM
$VNRX I’m excited for Vnrx this week!
1 · Reply
BinaryLogic
BinaryLogic Aug. 7 at 9:54 PM
$VNRX [Again] The Company is exposed to warrant conversions by its primary lender with a strained liquidity position and compliance risk (Aug-2027) near term - this is the reason for the massive fallout in-particular over the last 12mos. That said-the Company has more than 100 patents anchoring a published, peer-reviewed, studied, tested and commercialized for some derivatives diagnostic framework with multiple verticals including sepsis, inflammation, and cancer. They are currently in licensing discussions with more than 12 leading global diagnostic Companies, each multi-billion dollars in valuation. If/where the Company secures licensing deals, they will be comprised of up-front cash, milestone payments and double-digit royalties. This will resolve the near term liquidity constraint, create avenues for future (ongoing) revenue, further validate the underlying technology and bring the Company in compliance. $9.2M valuation, IP worth $150-250M, multiplier upside possible (IMO)
0 · Reply